0001237899-20-000008.txt : 20200214
0001237899-20-000008.hdr.sgml : 20200214
20200214160917
ACCESSION NUMBER: 0001237899-20-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200212
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STAHL NEIL
CENTRAL INDEX KEY: 0001226689
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20619697
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-12
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001226689
STAHL NEIL
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP Research and Development
Common Stock
2020-02-12
4
M
0
25000
52.03
A
36380
D
Common Stock
2020-02-12
4
F
0
14722
402.34
D
21658
D
Common Stock
2020-02-13
4
S
0
4302
399.8
D
17356
D
Common Stock
2020-02-13
4
S
0
2608
400.54
D
14748
D
Common Stock
2020-02-13
4
S
0
2058
401.46
D
12690
D
Common Stock
2020-02-13
4
S
0
1279
402.35
D
11411
D
Common Stock
2020-02-13
4
S
0
31
406.44
D
11380
D
Common Stock
5736
I
By 401(k) Plan
Common Stock
7831
I
by 2018 GRAT
Common Stock
13700
I
by 2019 GRAT
Non-Qualified Stock Option (right to buy)
52.03
2020-02-12
4
M
0
25000
0.0
D
2021-12-16
Common Stock
25000
63079
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 4,302 shares of Company stock on February 13, 2020 at prices ranging from $399.04 to $399.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 2,608 shares of Company stock on February 13, 2020 at prices ranging from $400.01 to $400.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 2,058 shares of Company stock on February 13, 2020 at prices ranging from $401.11 to $401.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
Represents volume-weighted average price of sales of 1,279 shares of Company stock on February 13, 2020 at prices ranging from $402.04 to $402.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price.
With respect to 75,000 underlying shares (of which 50,000 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 13,079 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.
/s/**Neil Stahl
2020-02-14